Matinas BioPharma Holdings, Inc. (MTNB)
After hours:
- GlobeNewswire
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference
- Thomson Reuters StreetEvents
Q1 2024 Matinas BioPharma Holdings Inc Earnings Call
Q1 2024 Matinas BioPharma Holdings Inc Earnings Call
- Insider Monkey
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript May 9, 2024 Matinas BioPharma Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome, everyone, to the Matinas BioPharma First Quarter 2024 Financial Results Conference Call. Currently, all […]
